Product Description
MEB-1170, was approved by the FDA on October 6th, 2022 to enter Phase 1 human clinical trials (see News tab). MEB-1170 is an oral analgesic to replace Oxycodone. It is designed and developed to treat pain without respiratorty depression which is the cause of death in overdoses. MEB-1170 shows no abuse potential in pre-clinical studies. MEB-1170 holds the promise to solve the opioid crisis. (Sourced from: https://mebiasdiscovery.com/pipeline/)
Mechanisms of Action: OPRM Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mebias Discover
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Pain Unspecified|Healthy Volunteers
Phase 0: Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MEB-1170-101 | P1 |
Unknown status |
Healthy Volunteers|Pain Unspecified |
2023-10-01 |